502 related articles for article (PubMed ID: 15133611)
1. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
Katsuno M; Adachi H; Tanaka F; Sobue G
J Mol Med (Berl); 2004 May; 82(5):298-307. PubMed ID: 15133611
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Adachi H; Inukai A; Sobue G
Cytogenet Genome Res; 2003; 100(1-4):243-51. PubMed ID: 14526186
[TBL] [Abstract][Full Text] [Related]
3. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.
Katsuno M; Adachi H; Doyu M; Minamiyama M; Sang C; Kobayashi Y; Inukai A; Sobue G
Nat Med; 2003 Jun; 9(6):768-73. PubMed ID: 12754502
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
Adachi H; Waza M; Katsuno M; Tanaka F; Doyu M; Sobue G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):135-51. PubMed ID: 17359355
[TBL] [Abstract][Full Text] [Related]
5. [Development of therapeutics for spinal and bulbar muscular atrophy (SBMA)].
Sobue G
Rinsho Shinkeigaku; 2003 Nov; 43(11):909-11. PubMed ID: 15152501
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.
Banno H; Katsuno M; Suzuki K; Takeuchi Y; Kawashima M; Suga N; Takamori M; Ito M; Nakamura T; Matsuo K; Yamada S; Oki Y; Adachi H; Minamiyama M; Waza M; Atsuta N; Watanabe H; Fujimoto Y; Nakashima T; Tanaka F; Doyu M; Sobue G
Ann Neurol; 2009 Feb; 65(2):140-50. PubMed ID: 19259967
[TBL] [Abstract][Full Text] [Related]
7. [Molecular-targeted therapy for spinal and bulbar muscular atrophy (SBMA)].
Sobue G
Rinsho Shinkeigaku; 2010 Nov; 50(11):839-41. PubMed ID: 21921465
[TBL] [Abstract][Full Text] [Related]
8. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.
Banno H; Adachi H; Katsuno M; Suzuki K; Atsuta N; Watanabe H; Tanaka F; Doyu M; Sobue G
Ann Neurol; 2006 Mar; 59(3):520-6. PubMed ID: 16358333
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Tanaka F; Adachi H; Banno H; Suzuki K; Watanabe H; Sobue G
Prog Neurobiol; 2012 Dec; 99(3):246-56. PubMed ID: 22609045
[TBL] [Abstract][Full Text] [Related]
10. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.
Thomas PS; Fraley GS; Damian V; Woodke LB; Zapata F; Sopher BL; Plymate SR; La Spada AR
Hum Mol Genet; 2006 Jul; 15(14):2225-38. PubMed ID: 16772330
[TBL] [Abstract][Full Text] [Related]
11. Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.
Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
Int J Mol Sci; 2009 Mar; 10(3):1000-12. PubMed ID: 19399234
[TBL] [Abstract][Full Text] [Related]
12. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model.
Adachi H; Waza M; Tokui K; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
J Neurosci; 2007 May; 27(19):5115-26. PubMed ID: 17494697
[TBL] [Abstract][Full Text] [Related]
13. Spinal and bulbar muscular atrophy.
Lieberman AP
Handb Clin Neurol; 2018; 148():625-632. PubMed ID: 29478604
[TBL] [Abstract][Full Text] [Related]
14. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein.
Adachi H; Katsuno M; Minamiyama M; Sang C; Pagoulatos G; Angelidis C; Kusakabe M; Yoshiki A; Kobayashi Y; Doyu M; Sobue G
J Neurosci; 2003 Mar; 23(6):2203-11. PubMed ID: 12657679
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Adachi H; Waza M; Banno H; Suzuki K; Tanaka F; Doyu M; Sobue G
Exp Neurol; 2006 Jul; 200(1):8-18. PubMed ID: 16513111
[TBL] [Abstract][Full Text] [Related]
16. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
[TBL] [Abstract][Full Text] [Related]
17. Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy.
Sahashi K; Katsuno M; Hung G; Adachi H; Kondo N; Nakatsuji H; Tohnai G; Iida M; Bennett CF; Sobue G
Hum Mol Genet; 2015 Nov; 24(21):5985-94. PubMed ID: 26231218
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy.
Montie HL; Cho MS; Holder L; Liu Y; Tsvetkov AS; Finkbeiner S; Merry DE
Hum Mol Genet; 2009 Jun; 18(11):1937-50. PubMed ID: 19279159
[TBL] [Abstract][Full Text] [Related]
19. X-Linked Spinal and Bulbar Muscular Atrophy: From Clinical Genetic Features and Molecular Pathology to Mechanisms Underlying Disease Toxicity.
Cortes CJ; La Spada AR
Adv Exp Med Biol; 2018; 1049():103-133. PubMed ID: 29427100
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogen flutamide protects male mice from androgen-dependent toxicity in three models of spinal bulbar muscular atrophy.
Renier KJ; Troxell-Smith SM; Johansen JA; Katsuno M; Adachi H; Sobue G; Chua JP; Sun Kim H; Lieberman AP; Breedlove SM; Jordan CL
Endocrinology; 2014 Jul; 155(7):2624-34. PubMed ID: 24742193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
